MOGAT2

Across TCGA pan-cancer cohorts, MOGAT2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MOGAT2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MOGAT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MOGAT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, UCEC, and PRAD are the cancer types where MOGAT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	II,III,IV	0.089	0.457	.015	12	view →
UCEC	DFS	Median	II,III,IV	1.000	0.487	.032	12	view →
PRAD	DFS	Median	All	0.047	0.935	<.001	6	view →
LUSC	OS	Median	All	0.326	0.728	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MOGAT2–UCS (DFS)

Open the UCS breakdown →